# New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
Canonical URL: https://biopharmsignal.com/news/MNOV/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation
Ticker: MNOV
Company: MediciNova
Source: MediciNova
Published: 2026-04-27 23:00 EST
Original Source URL: https://investors.medicinova.com
## Summary

LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National

## Article Body
LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National
## Recent Company News
- 2026-05-26 23:00 EST — [MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)](https://biopharmsignal.com/news/MNOV/medicinova-announces-completion-of-last-patient-last-visit-in-the-mn-001-natg-202-clinical-trial-of-mn-001-tipelukast) — Source: MediciNova
- 2026-04-27 23:00 EST — [New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation](https://biopharmsignal.com/news/MNOV/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation) — Source: MediciNova
- 2026-03-16 11:00 EST — [MediciNova to Participate at the 38th Annual ROTH Conference](https://biopharmsignal.com/news/MNOV/medicinova-to-participate-at-the-38th-annual-roth-conference) — Source: MediciNova
- 2026-01-29 23:00 EST — [MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients](https://biopharmsignal.com/news/MNOV/medicinova-announces-100-patients-enrolled-in-seanobi-study-expanded-access-program-eap-evaluating-mn-166-ibudilast-in-als-patients) — Source: MediciNova
- 2026-01-06 14:00 EST — [2026 New Year’s Greetings from the CEO](https://biopharmsignal.com/news/MNOV/2026-new-year-s-greetings-from-the-ceo) — Source: MediciNova
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)